Atai Beckley/$ATAI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Atai Beckley
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
Ticker
$ATAI
Sector
Primary listing
Employees
99
Headquarters
Website
Atai Beckley Metrics
BasicAdvanced
$1.5bn
-
-$2.44
1.61
-
Price and volume
Market cap
$1.5bn
Beta
1.61
52-week high
$5.51
52-week low
$3.27
Average daily volume
5m
Financial strength
Current ratio
10.017
Quick ratio
9.244
Long term debt to equity
1.221
Total debt to equity
1.377
Interest coverage (TTM)
-468.93%
Profitability
EBITDA (TTM)
-121.896
Gross margin (TTM)
-1,876.29%
Net profit margin (TTM)
-19,019.44%
Operating margin (TTM)
-3,490.80%
Effective tax rate (TTM)
0.09%
Revenue per employee (TTM)
$40,000
Management effectiveness
Return on assets (TTM)
-33.34%
Return on equity (TTM)
-378.00%
Valuation
Price to revenue (TTM)
316.397
Price to book
7.47
Price to tangible book (TTM)
7.59
Price to free cash flow (TTM)
-10.143
Free cash flow yield (TTM)
-9.86%
Free cash flow per share (TTM)
-0.4
Growth
Revenue change (TTM)
87.22%
Earnings per share change (TTM)
169.48%
3-year revenue growth (CAGR)
134.64%
3-year earnings per share growth (CAGR)
36.90%
Atai Beckley News
AllArticlesVideos
AtaiBeckley nears key clinical catalysts, Jefferies stays positive with repeat ‘Buy' rating
Proactive Investors·2 weeks ago
AtaiBeckley launches mental health patient impact grant program
Proactive Investors·3 weeks ago
AtaiBeckley clinical pipeline advances toward multiple late-stage data catalysts, Jefferies says
Proactive Investors·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs